ProQR Therapeutics N.V.
PRQR
Price:
$2.67
Market Cap:
$264.90M
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and researc...[Read more]
Industry
Biotechnology
IPO Date
2014-09-18
Stock Exchange
NASDAQ
Ticker
PRQR
PE Ratio
[-8.61]
ROE
[-71.11%]
Current Ratio
[2.33]
Dividend Yield
[0%]
Enterprise Value
[192.90M]
Dividend History
The ROE as of December 2024 (TTM) for ProQR Therapeutics N.V. (PRQR) is -71.11%
According to ProQR Therapeutics N.V.’s latest financial reports and current stock price. The company's current ROE is -71.11%. This represents a change of 276.03% compared to the average of -18.91% of the last 4 quarters.
ProQR Therapeutics N.V. (PRQR) Historical ROE (quarterly & annually)
How has PRQR ROE performed in the past?
The mean historical ROE of ProQR Therapeutics N.V. over the last ten years is -62.14%. The current -71.11% ROE has changed 14.43% with respect to the historical average. Over the past ten years (40 quarters), PRQR's ROE was at its highest in in the March 2015 quarter at 0.21%. The ROE was at its lowest in in the September 2022 quarter at -37.55%.
Average
-62.14%
Median
-64.05%
Minimum
-110.86%
Maximum
-11.08%
ProQR Therapeutics N.V. (PRQR) ROE by Quarter and Year
Discovering the peaks and valleys of ProQR Therapeutics N.V. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 217.22%
Maximum Annual ROE = -11.08%
Minimum Annual Increase = -100.30%
Minimum Annual ROE = -110.86%
| Year | ROE | Change |
|---|---|---|
| 2023 | -67.94% | -31.43% |
| 2022 | -99.07% | 82.85% |
| 2021 | -54.18% | -33.64% |
| 2020 | -81.65% | 35.72% |
| 2019 | -60.16% | 51.50% |
| 2018 | -39.71% | -64.18% |
| 2017 | -110.86% | 50.64% |
| 2016 | -73.59% | 217.22% |
| 2015 | -23.20% | 109.29% |
| 2014 | -11.08% | -100.30% |
ProQR Therapeutics N.V. (PRQR) Average ROE
How has PRQR ROE performed in the past?
The current ROE of ProQR Therapeutics N.V. (PRQR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-73.73%
5-year avg
-72.60%
10-year avg
-62.14%
ProQR Therapeutics N.V. (PRQR) ROE vs. Peers
How is PRQR’s ROE compared to its peers?
ProQR Therapeutics N.V.’s ROE is greater than Annexon, Inc. (-38.99%), greater than Arrowhead Pharmaceuticals, Inc. (-206.69%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Terns Pharmaceuticals, Inc. (-32.76%), less than Alnylam Pharmaceuticals, Inc. (323.66%), greater than Wave Life Sciences Ltd. (-251.35%), greater than Blueprint Medicines Corporation (-47.66%), greater than Apellis Pharmaceuticals, Inc. (-103.92%), greater than Assembly Biosciences, Inc. (-121.46%), less than Spero Therapeutics, Inc. (3.36%), greater than Achilles Therapeutics plc (-54.57%), greater than Instil Bio, Inc. (-37.44%), greater than Neoleukin Therapeutics, Inc. (-8.54%), greater than CytomX Therapeutics, Inc. (-41.34%), greater than NextCure, Inc. (-62.50%), greater than Nuvation Bio Inc. (-108.68%),
| Company | ROE | Market cap |
|---|---|---|
| -38.99% | $562.82M | |
| -206.69% | $2.46B | |
| -22.40% | $1.28B | |
| -32.76% | $503.69M | |
| 323.66% | $31.25B | |
| -251.35% | $2.00B | |
| -47.66% | $5.74B | |
| -103.92% | $4.13B | |
| -121.46% | $94.84M | |
| 3.36% | $50.31M | |
| -54.57% | $40.33M | |
| -37.44% | $141.74M | |
| -8.54% | $8.20M | |
| -41.34% | $85.30M | |
| -62.50% | $26.35M | |
| -108.68% | $898.63M |
Build a custom stock screener for ProQR Therapeutics N.V. (PRQR) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ProQR Therapeutics N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
ProQR Therapeutics N.V. (PRQR) and other stocks custom spreadsheet templates
The easiest way to analyze a company like ProQR Therapeutics N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is ProQR Therapeutics N.V.'s ROE?
How is the ROE calculated for ProQR Therapeutics N.V. (PRQR)?
What is the highest ROE for ProQR Therapeutics N.V. (PRQR)?
What is the 3-year average ROE for ProQR Therapeutics N.V. (PRQR)?
What is the 5-year average ROE for ProQR Therapeutics N.V. (PRQR)?
How does the current ROE for ProQR Therapeutics N.V. (PRQR) compare to its historical average?